Basal-like 1 triple-negative breast cancer (BL1)

What changed: Basal-like 1 triple-negative breast cancer (BL1)

Every dated change on the records linked to Basal-like 1 triple-negative breast cancer (BL1), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result2This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-24This recordBasal-like 1 triple-negative breast cancer (BL1)
Facts on this page last checked
When this page itself was last checked or edited.

2020 · 1

2020Trial resultKEYNOTE-522
KEYNOTE-522 reported
EFS HR 0.

2014 · 1

2014Trial resultGeparSixto
GeparSixto reported
Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.